<script type="text/javascript" src="https://pppbr.com/bnr.php?section=Footer46860&pub=543549&format=728x90&ga=g&bg=1"></script>
<noscript><a href="https://yllix.com/publishers/543549" target="_blank"><img src="//ylx-aff.advertica-cdn.com/pub/728x90.png" style="border:none;margin:0;padding:0;vertical-align:baseline;" alt="ylliX - Online Advertising Network" /></a></noscript>
Merck MRK, +0.05% and privately held Ridgeback Biotherapeutics said Wednesday the Japanese government has agreed to purchase $1.6 million courses of their COVID-19 antiviral molnupiravir, once it receives an authorization or approval. Merck and Ridgeback have applied for authorization of the treatment from the U.S. Food and Drug Administration, Japan’s Pharmaceuticals and Medical Devices Agency and the European Medicines Agency.
...read full article on Market Watch
